Nkarta, Inc. Common Stock
Symbol: NKTX (NASDAQ)
2.15
▲ (3.86%) 0.080
Company Description:
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Key Stats
- Today's Open: $2.07
- Today's High: $2.169
- Today's Low: $2.066
- Today's Volume: 182.84K
- Yesterday Close: $2.07
- Yesterday High: $2.14
- Yesterday Low: $2.04
- Yesterday Volume: 1.02M
- Last Min Volume: 139
- Last Min High: $2.15
- Last Min Low: $2.15
- Last Min VWAP: $2.15
Company Profile
- Name: Nkarta, Inc. Common Stock
- Website: https://www.nkartatx.com
- Listed Date: 2020-07-10
- Location: SOUTH SAN FRANCISCO, CA
- Market Status: Active
- CIK Number: 0001787400
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $147.02M
- Round Lot: 100
- Outstanding Shares: 71.02M
- Asset Type: CS
RECENT FILINGS FOR NKTX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-06-25 | 4 | View |
| 2025-06-25 | 3 | View |
| 2025-06-20 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-06 | 8-K | View |
| 2025-05-14 | 10-Q | View |
| 2025-05-14 | 8-K | View |
| 2025-04-21 | ARS | View |
| 2025-04-21 | DEFA14A | View |
Latest News on NKTX